Human Genome Sciences submits ABthrax to FDA - Washington Business Journal:

http://biomarck.com/intellectual-property.htm
On Thursday, Human Genome Sciences (NASDAQ: HGSI) announcede it had submitted a Biologics License Application to the FDA for its humajn monoclonal antibodydrug ABthrax, also known as for the treatment of inhalation anthrax. Human Genom e Sciences said the submission showed a survival benefit in studiexs of rabbits and monkeys and the result of safety studies conducted in healthhuman volunteers. “Based on the resultsz of our efficacy and safety we believe raxibacumab has the potential to be an importanyt new treatment for inhalation said Human Genome Sciences Senior Vice President Sally The U.S. government has already reachedthat conclusion.
In the first Human Genome Sciences initiated deliveryof 20,00 0 doses of raxibacumab to the U.S. Strategic National Stockpile for emergency use in the treatment of inhalation anthrax, generating $127.8 million in producty sales. Raxibacumab was developed under a contractr entered into in 2006 with the Biomedical Advancecd Research and Development Authority of the Office of the Assistant Secretarhy for Preparedness and Response ofthe U.S. Departmenyt of Health and Human Services. Raxibacumab is the firstf product that Human Genome Sciences has submitted for a BiologicxsLicense Application.
If it would mean a $10 million milestone paymentg for Human Genome Sciences under terme of theHHS contract.